在糖尿病病中SGLT2抑制剂和GLP-1受体激动剂:不断发展的证据和临床应用
Jae Hyun Bae1,2
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Diabetes & metabolism journal
|May 14, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂和类似葡萄糖-1 (GLP-1) 受体激活剂为糖尿病病患者提供了新的希望. 这些疗法除了血糖控制之外,还提供了显著的心脏和脏益处,改善了结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病病 (DKD) 是导致衰竭和心血管死亡的主要原因.
- 传统疗法在DKD管理中留下了相当大的残留风险.
- -葡萄糖共运输体2 (SGLT2) 抑制剂和类似葡萄糖-1 (GLP-1) 受体激活剂代表了一个新的治疗类.
研究的目的:
- 在DKD中审查SGLT2抑制剂和GLP-1受体激动剂对心脏和脏的益处.
- 为了评估这些药物的比较有效性.
- 概述DKD管理的未来方向,包括组合疗法和精准医学.
主要方法:
- 对具有里程碑意义的临床试验进行审查 (CREDENCE,DAPA-CKD,EMPA-KIDNEY,FLOW).
- 对作用机制 (血液动力学,抗炎,代谢) 的证据综合.
- 基于现有数据和间接比较的比较有效性的评估.
主要成果:
- SGLT2 抑制剂在降低淋巴细胞过和心力衰竭风险方面表现出有效性.
- GLP-1受体激动剂在减少白蛋白尿和动脉样硬化心血管事件方面有效.
- 具有里程碑意义的试验证实了这两类药物的脏保护和心血管益处.
结论:
- SGLT2抑制剂和GLP-1受体激动剂已经改变了DKD的治疗方法.
- 虽然SGLT2抑制剂可能提供更大的脏保护,但需要进行对比试验.
- 组合疗法和精准医学方法对优化DKD治疗结果具有前景.
相关概念视频
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:06Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
01:17Oral Hypoglycemic Agents: Sulfonylureas
197
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
197